CareTrust REIT, Inc. CTRE · NYSE
$36.64 +1.68% (+$0.61)
Summary
81 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 53% a year over the last 3 years.
- Out of every 100 USD of revenue, 65 USD is left as net profit.
- It earns 6.5 USD a year on every 100 USD of invested capital.
- It has raised its dividend 6 years in a row.
What to watch
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensivePrice against the Bulios Fair Price
P/E against its own last 5 years
P/E against the industry (REIT - Healthcare Facilities)
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 24.4 USD for 1 USD of yearly profit. Over the last five years it was 32.8 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 22% a year over 5 years. Over the last 3 years it grew by 36% a year. Earnings per share grew by 53% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 22 USD
- Sales and administration 8.3 USD
- Taxes and other 4.3 USD
- Net profit 65 USD
Net profit, industry median (REIT - Healthcare Facilities) 39 USD
Out of every 100 USD of revenue, 65 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.8 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, stretched- Yield
- 4.11%
- Paid out of profit
- 100%
- Raised in a row
- 6 years
You receive $1.50 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 13
- Hold 5
- Sell 1
Today's price within the analysts' price targets
The average target of $44 is 20% above today's price. 68% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Reportable Segment 100%
By region
The company reports no revenue by region.
Reportable Segment brings in 100% of revenue.
Segments in detail